{"id":"brl29060a","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug antagonizes cysteinyl leukotriene receptors (CysLT1 and/or CysLT2), which are key mediators of inflammation and bronchoconstriction. By blocking these receptors, BRL29060A reduces the inflammatory cascade involved in asthma and allergic airway disease, decreasing mucus production, airway edema, and smooth muscle contraction.","oneSentence":"BRL29060A is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors to reduce inflammatory responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:47:23.252Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma"}]},"trialDetails":[{"nctId":"NCT00557622","phase":"PHASE2","title":"Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2008-01-25","conditions":"Post-Traumatic Stress Disorder, Stress Disorders, Post-Traumatic","enrollment":5},{"nctId":"NCT00839397","phase":"PHASE3","title":"BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-05","conditions":"Post-Traumatic Stress Disorder","enrollment":52},{"nctId":"NCT00318669","phase":"PHASE3","title":"Social Anxiety Disorder Study Of Paroxetine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-12","conditions":"Social Phobia","enrollment":390},{"nctId":"NCT00264654","phase":"PHASE3","title":"Long-term Study Of Paroxetine in Women and Men","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-10","conditions":"Social Phobia","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BRL29060A","genericName":"BRL29060A","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BRL29060A is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors to reduce inflammatory responses. Used for Asthma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}